Compare Microbot Medical, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 183 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.02
-16.71%
2.34
Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2025)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.02%
0%
21.02%
6 Months
3.9%
0%
3.9%
1 Year
-15.14%
0%
-15.14%
2 Years
123.55%
0%
123.55%
3 Years
91.89%
0%
91.89%
4 Years
-63.15%
0%
-63.15%
5 Years
-69.7%
0%
-69.7%
Microbot Medical, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-19.48%
EBIT to Interest (avg)
-10.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.05
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.39%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.34
EV to EBIT
-7.37
EV to EBITDA
-7.40
EV to Capital Employed
-61.16
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-16.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 5 Schemes (5.9%)
Foreign Institutions
Held by 24 Foreign Institutions (2.39%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.10
-3.40
-20.59%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.50
-3.40
-2.94%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -2.94% vs -6.25% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-14.70
-11.50
-27.83%
Interest
0.00
0.00
Exceptional Items
0.30
0.00
Consolidate Net Profit
-13.10
-11.40
-14.91%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -14.91% vs -6.54% in Dec 2024
About Microbot Medical, Inc. 
Microbot Medical, Inc.
Pharmaceuticals & Biotechnology
Microbot Medical Inc. is a pre-clinical medical device company. The Company is focused on the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms, ViRob, TipCAT and Liberty, including certain CardioSert assets, are comprised of proprietary technologies. Using the ViRob platform, Microbot is developing the Self Cleaning Shunt (SCSTM) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH). Utilizing the Liberty and CardioSert platforms, it is developing disposable robot for various endovascular interventional procedures. ViRob technology is an autonomous crawling micro-robot. TipCAT is a disposable self-propelled locomotive device. Liberty is a disposable robotic system.
Company Coordinates 
Company Details
25 RECREATION PARK DR SUITE 108 , HINGHAM MA : 02043
Registrar Details






